Childhood vaccine schedule aggressiveness & autism diagnosis rates across developed nations

Notes on the data

About the methodology

Comparing autism rates across countries is genuinely hard because the underlying methods differ. The U.S. CDC ADDM Network reviews health and education records at age 8; Australia runs a household self-report survey; Japan has both a low-yield national claims database and high-yield research cohorts; Nordic countries rely on conservative national registries; the UK uses GP records. Wherever possible this comparison uses the methodology closest to U.S. ADDM (record-based surveillance covering most cases). Where a country only publishes a method that under- or over-counts, that's flagged. U.S. schedule data reflects the 2024 CDC recommendations — the schedule in effect for the birth cohorts whose autism rates we're measuring today.

Why some countries are flagged as having unreliable autism data

• France. Active under-identification. Advocacy groups and EU-funded research estimate only about 15% of autistic individuals are diagnosed in France. Diagnostic culture historically leaned on psychoanalytic frameworks, which delayed adoption of DSM-based screening. The widely-cited "1 in 144" figure reflects diagnoses, not true prevalence.
• Germany. No nationwide ASD prevalence study exists. The 0.8% figure comes from outpatient claims data for ages 0–24, which captures only diagnosed cases. The OECD notes Germany's identification systems lag those of peer countries. True prevalence is likely 2–3× the recorded rate.
• Sweden. The national registry uses ICD-10 with conservative interpretation (yielding ~0.5–0.7%), while screening-based studies in Gothenburg and Stockholm County have found 2.5–3.7% prevalence. The number used here reflects the registry; the true rate is higher.
• Norway. Register-based 0.6% is similarly conservative. Iceland — using the same broad Nordic healthcare model but more proactive screening — finds 2.4–3.1%, suggesting Norway's number understates true prevalence substantially.

Outliers and curiosities worth noting

• The U.S. has both the most aggressive 2024-era schedule and the highest reliably-measured autism diagnosis rate (32.3 per 1,000, from CDC ADDM 8-year-old surveillance). When countries are measured with comparable record-based methodologies, no peer nation exceeds the U.S.
• Australia presents two very different numbers depending on methodology. The ABS household self-report survey finds 4.3% of 5–14 year olds (43 per 1,000), but the NSW data-linkage study — methodologically closest to CDC ADDM — finds 1.3% by age 12. The lower number is used here for fair comparison. The household-survey figure is likely inflated by NDIS funding incentives that reward formal diagnosis.
• Japan's most intensive research cohort (Hirosaki, ages 5) found 3.2% — but this used proactive active screening, not the passive record review that the CDC uses. Japan's national health insurance claims data shows ~1.5–1.8%, much closer to what the US ADDM methodology would measure.
• Denmark deliberately keeps its schedule minimal. Its public health authority has stated on record that adding non-essential vaccines could erode trust in the core program. Denmark's autism rate is moderate (~14.7 per 1,000 for school-aged children).
• The UK starts its core schedule at 8 weeks (same age as the U.S.) but uses fewer doses and no birth Hep B for low-risk infants. Its autism rate sits between Denmark and the U.S.

Sources